陕西省川崎病诊疗中心。
Shaanxi Provincial Diagnosis and Treatment Center of Kawasaki Disease.
出版信息
Zhongguo Dang Dai Er Ke Za Zhi. 2021;23(9):867-876. doi: 10.7499/j.issn.1008-8830.2107110.
Abstract
Kawasaki disease is an acute, self-limited vascuitis that mainly occurs in children under 5 years of age. Intravenous immunoglobulin (IVIG) has become an effective treatment regimen, which can effectively reduce the incidence of cardiovascular complications. However, there has been no consensus or clinical guidelines for the application of IVIG in children with Kawasaki disease till now. This consensus is developed based on the current research progress on the application of IVIG in children with Kawasaki disease in China and overseas, with reference to the diagnosis and treatment guidelines for Kawasaki disease in China and overseas, and the opinions of experts. This consensus provides recommendations on the clinical application strategy of IVIG in children with Kawasaki disease and the prevention and treatment of its adverse reactions. .
摘要
川崎病是一种主要发生于 5 岁以下儿童的急性、自限性血管炎。静脉注射免疫球蛋白（IVIG）已成为一种有效的治疗方案，可有效降低心血管并发症的发生率。然而，目前对于川崎病患儿 IVIG 的应用尚未达成共识或临床指南。本共识是基于国内外目前关于川崎病患儿 IVIG 应用的研究进展，参考国内外川崎病的诊断和治疗指南以及专家意见制定的。本共识就川崎病患儿 IVIG 的临床应用策略及不良反应的防治提供了推荐意见。
相似文献
1
Shaanxi Provincial Diagnosis and Treatment Center of Kawasaki Disease.陕西省川崎病诊疗中心。
Zhongguo Dang Dai Er Ke Za Zhi. 2021;23(9):867-876. doi: 10.7499/j.issn.1008-8830.2107110.
2
Pediatric expert consensus on the application of glucocorticoids in Kawasaki disease.川崎病糖皮质激素应用的儿科专家共识
Zhongguo Dang Dai Er Ke Za Zhi. 2022 Mar 15;24(3):225-231. doi: 10.7499/j.issn.1008-8830.2112033.
3
[Pediatric expert consensus on the application of aspirin in Kawasaki disease].[川崎病应用阿司匹林的儿科专家共识]
Zhongguo Dang Dai Er Ke Za Zhi. 2022 Jun 15;24(6):597-603. doi: 10.7499/j.issn.1008-8830.2203190.
4
[Evidence-based guidelines for the diagnosis and treatment of Kawasaki disease in children in China (2023)].《中国儿童川崎病诊断与治疗循证指南（2023年版）》
Zhongguo Dang Dai Er Ke Za Zhi. 2023 Dec 15;25(12):1198-1210. doi: 10.7499/j.issn.1008-8830.2309038.
6
Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.川崎病的诊断、治疗及长期管理：美国心脏协会青少年心血管疾病理事会风湿热、心内膜炎及川崎病委员会为卫生专业人员发布的声明
Pediatrics. 2004 Dec;114(6):1708-33. doi: 10.1542/peds.2004-2182.
7
Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.川崎病的诊断、治疗及长期管理：美国心脏协会青少年心血管疾病理事会风湿热、心内膜炎及川崎病委员会给卫生专业人员的声明
Circulation. 2004 Oct 26;110(17):2747-71. doi: 10.1161/01.CIR.0000145143.19711.78.
8
Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.静脉注射免疫球蛋白联合泼尼松龙治疗川崎病的疗效和安全性（Post RAISE）：一项多中心前瞻性队列研究。
Lancet Child Adolesc Health. 2018 Dec;2(12):855-862. doi: 10.1016/S2352-4642(18)30293-1. Epub 2018 Oct 16.
9
Intravenous immunoglobulin treatment responsiveness depends on the degree of CD8+ T cell activation in Kawasaki disease.静脉注射免疫球蛋白治疗反应性取决于川崎病中CD8 + T细胞的活化程度。
Clin Immunol. 2016 Oct;171:25-31. doi: 10.1016/j.clim.2016.08.012. Epub 2016 Aug 9.
10
Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.土耳其儿童川崎病：单中心经验，重点关注静脉注射免疫球蛋白抵抗和巨大冠状动脉瘤
Turk J Pediatr. 2019;61(5):648-656. doi: 10.24953/turkjped.2019.05.002.
引用本文的文献
1
Clinical prediction of intravenous immunoglobulin-resistant Kawasaki disease based on interpretable Transformer model.基于可解释Transformer模型的静脉注射免疫球蛋白抵抗性川崎病的临床预测
PLoS One. 2025 Jul 9;20(7):e0327564. doi: 10.1371/journal.pone.0327564. eCollection 2025.
2
[DeepSeek perspective on managing Kawasaki disease in Chinese children].[DeepSeek对中国儿童川崎病管理的观点]
Zhongguo Dang Dai Er Ke Za Zhi. 2025 May 15;27(5):524-528. doi: 10.7499/j.issn.1008-8830.2502042.
3
[Development of a predictive scoring model for non-response to intravenous immunoglobulin in Kawasaki disease].[川崎病静脉注射免疫球蛋白无反应的预测评分模型的开发]
Zhongguo Dang Dai Er Ke Za Zhi. 2025 Jan 15;27(1):75-81. doi: 10.7499/j.issn.1008-8830.2408077.
4
Guideline for the diagnosis and treatment of incomplete Kawasaki disease in children in China.中国儿童不完全川崎病诊断与治疗指南。
BMC Pediatr. 2024 Jul 26;24(1):477. doi: 10.1186/s12887-024-04961-2.
5
[Predictive value of peripheral blood lymphocyte subsets for children with intravenous immunoglobulin-resistant Kawasaki disease].[外周血淋巴细胞亚群对静脉注射免疫球蛋白抵抗型川崎病患儿的预测价值]
Zhongguo Dang Dai Er Ke Za Zhi. 2023 Dec 15;25(12):1211-1218. doi: 10.7499/j.issn.1008-8830.2305067.
6
[Evidence-based guidelines for the diagnosis and treatment of Kawasaki disease in children in China (2023)].《中国儿童川崎病诊断与治疗循证指南（2023年版）》
Zhongguo Dang Dai Er Ke Za Zhi. 2023 Dec 15;25(12):1198-1210. doi: 10.7499/j.issn.1008-8830.2309038.
7
[Diagnosis and treatment of incomplete Kawasaki disease in children].[儿童不完全川崎病的诊断与治疗]
Zhongguo Dang Dai Er Ke Za Zhi. 2023 Mar 15;25(3):238-243. doi: 10.7499/j.issn.1008-8830.2209127.
8
A global bibliometric analysis on Kawasaki disease research over the last 5 years (2017-2021).近 5 年（2017-2021 年）川崎病研究的全球文献计量学分析。
Front Public Health. 2023 Jan 10;10:1075659. doi: 10.3389/fpubh.2022.1075659. eCollection 2022.
9
Pediatric expert consensus on the application of glucocorticoids in Kawasaki disease.川崎病糖皮质激素应用的儿科专家共识
Zhongguo Dang Dai Er Ke Za Zhi. 2022 Mar 15;24(3):225-231. doi: 10.7499/j.issn.1008-8830.2112033.
本文引用的文献
1
2021 Update on the Clinical Management and Diagnosis of Kawasaki Disease.2021年川崎病临床管理与诊断的最新进展
Curr Infect Dis Rep. 2021;23(3):3. doi: 10.1007/s11908-021-00746-1. Epub 2021 Feb 6.
2
Sodium-containing versus sodium-trace preparations of IVIG for children with Kawasaki disease in the acute phase.含钠与微量钠静脉注射免疫球蛋白制剂治疗川崎病急性期儿童的比较。
Eur J Pediatr. 2021 Nov;180(11):3279-3286. doi: 10.1007/s00431-021-04096-x. Epub 2021 May 10.
3
High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China.《高剂量静脉注射免疫球蛋白治疗重症 2019 冠状病毒病：中国多中心回顾性研究》。
Front Immunol. 2021 Feb 19;12:627844. doi: 10.3389/fimmu.2021.627844. eCollection 2021.
4
Kawasaki Disease in the Australian Population: An Australian Tertiary Hospital Experience.澳大利亚人群中的川崎病：澳大利亚一所三级医院的经验。
Heart Lung Circ. 2021 Jul;30(7):996-1001. doi: 10.1016/j.hlc.2020.12.016. Epub 2021 Feb 19.
5
[Middle and long-term follow-up of 101 children with giant coronary artery aneurysm of Kawasaki disease].[101例川崎病巨大冠状动脉瘤患儿的中长期随访]
Zhonghua Er Ke Za Zhi. 2021 Feb 2;59(2):101-106. doi: 10.3760/cma.j.cn112140-20201124-01052.
6
Risk Factors of Coronary Artery Abnormalities and Resistance to Intravenous Immunoglobulin Plus Corticosteroid Therapy in Severe Kawasaki Disease: An Analysis of Post RAISE.川崎病重度患儿冠状动脉异常及静脉用免疫球蛋白联合糖皮质激素治疗抵抗的危险因素：RAISE 后分析
Circ Cardiovasc Qual Outcomes. 2021 Feb;14(2):e007191. doi: 10.1161/CIRCOUTCOMES.120.007191. Epub 2021 Feb 5.
7
Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease.意大利儿科学会关于川崎病一般治疗的修订建议。
Ital J Pediatr. 2021 Jan 25;47(1):16. doi: 10.1186/s13052-021-00962-4.
8
Effect of Early Intravenous Immunoglobulin Therapy in Kawasaki Disease: A Systematic Review and Meta-Analysis.早期静脉注射免疫球蛋白治疗川崎病的效果：一项系统评价与荟萃分析
Front Pediatr. 2020 Nov 20;8:593435. doi: 10.3389/fped.2020.593435. eCollection 2020.
9
Use of premedication with intravenous immune globulin in Kawasaki disease: A retrospective review.川崎病中静脉注射免疫球蛋白的预用药：回顾性研究。
Pediatr Allergy Immunol. 2021 May;32(4):750-755. doi: 10.1111/pai.13432. Epub 2021 Jan 18.
10
Update on the Management of Kawasaki Disease.川崎病治疗进展
Pediatr Clin North Am. 2020 Oct;67(5):811-819. doi: 10.1016/j.pcl.2020.06.002. Epub 2020 Aug 11.
Zotero 插件